BACKGROUNDSystemic, high–dose interferon‐α treatment given three times per week subcutaneously induces tumor regression in approximately 30% of patients with inoperable hepatocellular carcinoma (HCC). The objective of the current study was to determine the efficacy and safety of transcatheter arterial interferon embolization for the treatment of patients with inoperable HCC.METHODSEighteen patients with inoperable HCC were recruited to receive 3 different doses of interferon‐α‐2b (10 megaunits [MU]/m2, 30 MU/m2, or 50 MU/m2) at intervals of 8–12 weeks. Their tumor response, adverse events, and survival were monitored.RESULTSIn 14 patients with nondiffuse HCC, complete responses and partial responses (> 50% tumor reduction) were observed in 28.6% and 35.7% of patients, respectively. One of four patients with diffuse HCC had a partial response. Thirty‐eight percent of patients had normalization of their α‐fetoprotein level. The median ferritin level at the last follow‐up was reduced significantly (765 pmol/L; range, 457–2720 pmol/L) compared with the baseline level (1980 pmol/L; range, 1100–3300 pmol/L; P = 0.011). The median survival was 15.9 months. Transient fever and rigor were the most common side effects observed. Five patients (27.8%) developed hypothyroidism. No significant liver decompensation was observed.CONCLUSIONSThis pilot study showed that transcatheter arterial interferon embolization was an effective method for the treatment of patients with inoperable HCC without significant hepatic toxicity. Cancer 2003;97:2776–82. © 2003 American Cancer Society.DOI 10.1002/cncr.11400
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.